Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834801 | 0.92 | NSD2 (0.54) | NSD2EHMT2PIK3CAKDM1ARCOR1 | |
| SCHEMBL29834658 | 0.90 | CNR1 (0.47) | NSD2EHMT2PIK3CAKDM1ARCOR1 | |
| SCHEMBL28983513 | 0.81 | PIK3CD (0.49) | PIK3CAGPR119PIK3CDEGFR | |
| SCHEMBL29686088 | 0.81 | PIK3CD (0.49) | PIK3CAGPR119PIK3CDEGFR | |
| SCHEMBL29834627 | 0.81 | NSD2 (0.54) | NSD2EHMT2PIK3CAKDM1ARCOR1 | |
| SCHEMBL23359653 | 0.75 | EPHX2 (0.54) | ALDH1A1GPR119NPC1MAPTMAPK1 | |
| SCHEMBL29834688 | 0.75 | EGFR (0.58) | EGFR | |
| SCHEMBL30822064 | 0.75 | ENPP1 (0.49) | PIK3CAGPR119PIK3CDEGFR | |
| SCHEMBL24714039 | 0.75 | ENPP1 (0.49) | PIK3CAGPR119PIK3CDEGFR | |
| SCHEMBL27145372 | 0.74 | EGFR (0.57) | NSD2EHMT2PIK3CADNMT3APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | NSD2 1898/4885EHMT2 4166/4885PIK3CA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.